Despite the numerous challenges that still need to be addressed, on the basis of our current animal trials, autocrine VEGF-B signaling of T cells is expected to be a therapeutic target against infection and tumors and a treatment of autoimmune diseases. Here, VEGFB is linked to autoimmune disease.